Sign in to view content

Effect of 6 month anti-VEGF treatment for proliferative diabetic retinopathy on the quantitative metrics of the retinal microvasculature on OCTA

Quan V. Hoang, MD, PhD

Video
Published 2019

Related

2 Real-World Analyses of Treatment Burden Associated With Intravitreal Injections for DME Prior to 0.2 mcg/Day Fluocinolone Acetonide (FAc)
Nancy M. Holekamp, MD, FASRS
Annual Meeting Talks
2018
Loss to Follow-up in Patients With Proliferative Diabetic Retinopathy Treated With Anti-VEGF Therapy and/or PRP in the United States
Rahul N. Khurana, MD, FASRS
Updates from the Field
2021
Novel Vascular Endothelial Growth-Factor A (VEGF-A) and Angiopoietin-2 (Ang-2) Bispecific Protein, RO-634, in Comparison to Aflibercept
Mark R. Barakat, MD
Annual Meeting Talks
2022

Category: Diabetic Retinopathy

See more